摘要
目的评价Alu-qPCR检测肺结节患者血浆cfDNA浓度及凋亡指数在鉴别结节良、恶性中的应用价值。方法收集纯化70例肺部结节患者血浆,检测cfDNA浓度、凋亡指数及肿瘤蛋白标记物,并分析上述指标与患者临床特征的关系。结果非小细胞肺癌组与肺部良性结节组血浆短片段cfDNA平均含量为129.86、91.12 ng/mL(P>0.05),长片段cfDNA平均含量为33.95、38.24 ng/mL(P<0.05)。平均凋亡指数9.44、5.35(F<0.05)。长片段cfDNA浓度、DNA凋亡指数可作为潜在诊断指标,对应临界值:6.22、29.50 ng/mL,灵敏度:0.63、0.74,特异度:0.77、0.85。良、恶性结节患者肿瘤标记物水平统计学差异不显著。结论cfDNA检测在肺结节性质判断方面具有潜在应用价值,可为术前结节性质判定提供参考。肿瘤标记物在监测肿瘤转移、复发中意义较大。
Objective To evaluate the value of cfDNA segment concentration testing and apoptosis index calculation in differentiating benign and malignant pulmonary nodules.Methods We collected and purified the plasma of patients with pulmonary nodules,evaluated the cfDNA concentration,apoptosis index,and traditional tumor protein markers.Their relationship with clinicopathological parameters was analyzed.Results The short fragments content of malignant pulmonary node and benign pulmonary node patients was 129.86,91.12 ng/mL(P>0.05).Long fragments content was 33.95,38.24 ng/mL(P<0.05),and apoptosis index was 9.44,5.35(P<0.05).Long fragment cfDNA concentration,apoptosis index can be used as potential detection indexes.Critical value was 6.22,29.50 ng/mL.Corresponding sensitivity was 0.63,0.74,corresponding.Specificity was 0.77,0.85.The level of tumor markers in patients with benign and malignant nodules was not statistically significant.Conclusion cfDNA detection has potential application value in judging the nature of pulmonary nodules,which can indicate the pathological properties of pulmonary nodules.Tumor markers have a suggestive effect on the invasion and metastasis of known pathological types of pulmonary nodules,which can be used for metastasis and recurrence monitoring.Combine those two indexes can provide a reference for the clinical intervention of pulmonary nodules in diSerent periods.
作者
王宇轩
苏崇玉
刘志东
Wang Yuxuan;Su Chongyu;Liu Zhidong(Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital,Capital Medical University,Beijing 101149,China)
出处
《结核病与胸部肿瘤》
2021年第2期126-131,共6页
Tuberculosis and Thoracic Tumor
基金
北京市通州区科技计划(编号:KJ2019CX007)。